Selarsdi, ustekinumab-aekn (biosimilar to Stelara)
Named-patient access overview. Selarsdi is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Selarsdi
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Selarsdi
Selarsdi (ustekinumab-aekn) is a biosimilar to Stelara, developed by Alvotech and commercialized in the United States by Teva Pharmaceuticals. It was approved by the US FDA in 2024 for moderate-to-severe plaque psoriasis in adults and pediatric patients six years and older, and for active psoriatic arthritis in adults, following the reference product's approved indication scope.
The molecule is a fully human monoclonal antibody that binds the shared p40 subunit of interleukin-12 and interleukin-23, blocking downstream signaling on T cells, NK cells, and antigen-presenting cells implicated in psoriatic inflammation. Selarsdi is administered subcutaneously, typically with a loading regimen followed by maintenance dosing every twelve weeks.
Selarsdi may be accessible to international patients through Named Patient Program or personal-import pathways. As a biosimilar to Stelara, it is indicated within the reference product's approved scope and is not a novel molecule.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Selarsdi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Selarsdi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Selarsdi is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list ustekinumab as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Selarsdi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Selarsdi
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Selarsdi if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Selarsdi for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Selarsdi through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Selarsdi. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Selarsdi through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Selarsdi to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Selarsdi to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Selarsdi cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Selarsdi?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.